UnitedHealthcare · SCS Traditional · US health-plan appeal rights

SCS Traditional denied as experimental or investigational by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare SCS Traditional denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

UnitedHealthcare's specific coverage criteria for scs traditional are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: UHC Commercial: Spinal Cord and Dorsal Root Ganglion Stimulators (mirrors NACC + CMS NCD 160.7)

The UnitedHealthcare angle on SCS Traditional

## Why UnitedHealthcare Denies Traditional Spinal Cord Stimulation as Experimental

An experimental or investigational denial from UnitedHealthcare asserts that the evidence base for traditional spinal cord stimulation (SCS) does not yet meet the plan's internal standard for clinical effectiveness. This denial type is particularly frustrating because traditional SCS has been in clinical use for decades and carries FDA approval for specific pain indications — yet plans retain the contractual right to apply their own evidence-review criteria, which may lag behind professional society consensus.

## Why This Denial Is Appealable

Traditional SCS is not investigational for established indications. The FDA cleared implantable SCS systems for use as an aid in the management of chronic intractable pain of the trunk and/or limbs. When a denial characterizes an FDA-cleared device as experimental for an on-label indication, it is directly contradicted by the regulatory record. Your appeal should draw a sharp line between the device's cleared status and the plan's characterization, and should document that your specific indication falls within the cleared use.

## Federal Appeal Framework

Internal appeal (ACA §2719 / ERISA §503): Submit a written appeal within the deadline in the denial letter. Include a cover letter identifying the specific claim that traditional SCS is experimental and why that claim is factually incorrect for your indication.
Independent external review: External reviewers are clinicians in the relevant specialty. An expert reviewer who performs SCS implants is unlikely to characterize cleared, guideline-supported therapy as investigational. Request external review promptly — the window is typically around four months from the final internal denial, though your denial letter governs.
Expedited track: Available if clinical urgency exists.
State and federal regulators: If the plan's experimental classification contradicts FDA clearance, consider filing a complaint with your state insurance commissioner and, for self-funded plans, the U.S. Department of Labor.

## Documentation to Gather

FDA clearance documentation: A copy of the FDA 510(k) clearance or PMA approval for the specific SCS system being requested, confirming its cleared indication.
On-label indication match: A letter from your implanting physician confirming that your clinical situation falls within the FDA-cleared indication.
Professional society position statements: Statements from the North American Neuromodulation Society, the American Society of Interventional Pain Physicians, or other relevant specialty societies affirming SCS as an accepted, non-investigational treatment for your condition.
Peer-reviewed literature: Your physician may cite systematic reviews or meta-analyses supporting SCS effectiveness — without you needing to cite specific statistics, your physician's letter can reference this literature by name.
Clinical severity and prior-treatment failure: Document that you have exhausted less invasive options, as guideline support for SCS typically requires this.

## Criteria-Mapping Structure

Obtain UHC's current coverage determination policy for spinal cord stimulation and identify every criterion listed under their "experimental/investigational" definition. Your appeal letter should methodically address each element: FDA clearance status, peer-reviewed evidence base, professional society acceptance, and clinical appropriateness for your specific diagnosis. Present each rebuttal point as a numbered response to the plan's stated rationale.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other insurers on SCS Traditional

Other denial reasons for UnitedHealthcare SCS Traditional

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.